Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Queensland Health
Johnson and Johnson
Federal Trade Commission

Generated: June 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,591,454

« Back to Dashboard

Summary for Patent: 5,591,454
Title: Method for lowering blood glucose
Abstract:The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
Inventor(s): Kuczynski; Anthony L. (Mountain View, CA), Ayer; Atul D. (Palo Alto, CA), Wong; Patrick S.-L. (Palo Alto, CA)
Assignee: ALZA Corporation (Palo Alto, CA)
Application Number:08/442,040
Patent Claims: 1. A method for treating hyperglycemia in a patient, wherein the method comprises administering to the patient a dosage form comprising 2 mg to 750 mg glipizide that is administered at a therapeutically effective dose of 10 ng to 25 mg over 24 hours from the dosage form comprising 1 mg to 300 osmagent and a hydrogel selected from the group consisting of poly(ethylene oxide) having a 4,000,000 to 8,000,000 molecular weight and a carboxymethylcellulose having a 200,000 to 1,000,000 molecular weight to the patient to produce the intended effect in the patient.

2. A method for treating hyperglycemia in a patient, wherein the method comprises administering to the patient a dosage form comprising a composition that comprises 2.0 mg to 750 mg of a glipizide that is administered at a dose of 10 ng to 25 mg per hour over an extended period of 24 hours, from the composition that comprises 100 mg to 320 mg of a poly(ethylene oxide) having a 80,000 to 350,000 molecular weight and 5 mg to 50 mg of a hydroxypropylmethylcellulose having a 9,200 to 22,000 molecular weight to produce the intended therapy.

3. A method for lowering blood sugar in the treatment of a diabetic patient, which method comprises orally administering to the patient an effective blood sugar lowering dose of a composition comprising glipizide and a pharmaceutically acceptable carrier, which carrier comprises 100 mg to 250 mg of a hydroxypropylmethylcellulose of 40,000 to 80,000 molecular weight and 40 mg to 70 mg of polyvinylpyrrolidone of 30,000 to 70,000 molecular weight, which blood sugar lowering composition is administered over time to produce the intended lowering of the blood sugar in the patient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Farmers Insurance
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.